These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32953720)

  • 1. Real-world data on the effectiveness and safety of interferon-alpha-2a intralesional injection for the treatment of focally recalcitrant mycosis fungoides.
    Zhang SY; Liu ZR; Yang L; Wang T; Liu J; Liu YH; Fang K
    Ann Transl Med; 2020 Aug; 8(15):920. PubMed ID: 32953720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.
    Hu JK; Carlson K; Girardi M
    Yale J Biol Med; 2020 Mar; 93(1):41-44. PubMed ID: 32226334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.
    Wu PA; Huang V; Bigby ME
    Br J Dermatol; 2014 May; 170(5):1015-20. PubMed ID: 24841586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of interferon-α2a as monotherapy in stage IB patients with mycosis fungoides: A retrospective chart review of patient outcomes.
    Gökşin Ş; İmren IG; Cenk H; Kaçar N; Duygulu Ş
    Dermatol Ther; 2022 Apr; 35(4):e15344. PubMed ID: 35094466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for mycosis fungoides.
    Weberschock T; Strametz R; Lorenz M; Röllig C; Bunch C; Bauer A; Schmitt J
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008946. PubMed ID: 22972128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe and efficacious use of intralesional steroids for the treatment of focally resistant mycosis fungoides.
    Liu DY; Shaath T; Rajpara AN; Hanson C; Fraga G; Fischer R; Aires DJ
    J Drugs Dermatol; 2015 May; 14(5):466-71. PubMed ID: 25942664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome.
    Kuzel TM; Roenigk HH; Samuelson E; Herrmann JJ; Hurria A; Rademaker AW; Rosen ST
    J Clin Oncol; 1995 Jan; 13(1):257-63. PubMed ID: 7799028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.
    Chiarion-Sileni V; Bononi A; Fornasa CV; Soraru M; Alaibac M; Ferrazzi E; Redelotti R; Peserico A; Monfardini S; Salvagno L
    Cancer; 2002 Aug; 95(3):569-75. PubMed ID: 12209749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of results of short-term low dose interferon-α-2b combined with PUVA in the treatment of early stage mycosis fungoides.
    Şahin F; Kılınç Karaarslan I; Akad Soyer N; Vural F; Ocakcı S; Öztürk G; Özen KP; Saydam G
    Turk J Haematol; 2006 Dec; 23(4):188-92. PubMed ID: 27265660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes.
    Gökdemir G; Barutcuoglu B; Sakiz D; Köşlü A
    J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):804-9. PubMed ID: 16898902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation.
    Alberti-Violetti S; Ardigò M; Massone C; Pileri A; Sala R; Teoli M; Grandi V; Quaglino P; Pimpinelli N; Berti E
    Front Oncol; 2023; 13():1298296. PubMed ID: 38239642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
    J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of cytokine genes and bcl-2 expression following immunotherapy with intralesional IFN-gamma in a patient with tumor-stage mycosis fungoides.
    Yamamoto T; Takahashi Y; Katayama I; Nishioka K
    Dermatology; 1998; 196(3):283-7. PubMed ID: 9621132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement.
    Doerschner M; Pekar-Lukacs A; Messerli-Odermatt O; Dommann-Scherrer C; Rütti M; Müller AM; Nair G; Kamarachev J; Kerl K; Beer M; Messerli M; Frauenknecht K; Haralambieva E; Hoetzenecker W; French LE; Guenova E
    Br J Dermatol; 2019 Dec; 181(6):1296-1302. PubMed ID: 30565216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series.
    Kyvernitakis A; Duvic M; Mahale P; Torres HA
    Am J Clin Dermatol; 2014 Oct; 15(5):451-6. PubMed ID: 24934807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial.
    Ortiz-Romero PL; Maroñas Jiménez L; Muniesa C; Estrach T; Servitje O; Fernández-de-Misa R; Gallardo F; Sanmartín O; Riveiro-Falkenbach E; García-Díaz N; Vega R; Lora D; Postigo C; Jiménez B; Sánchez-Beato M; Pedro Vaqué J; Rodríguez Peralto JL; de la Cámara AG; de la Cruz J; Piris Pinilla MÁ
    Lancet Haematol; 2022 Jun; 9(6):e425-e433. PubMed ID: 35654076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides?
    Roberge D; Muanza T; Blake G; Shustik C; Vuong T; Freeman CR
    Br J Dermatol; 2007 Jan; 156(1):57-61. PubMed ID: 17199567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
    Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
    J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
    Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
    J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.